Edesa Biotech (EDSA) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Edesa Biotech, a clinical-stage biopharmaceutical company, has announced its participation in several investor conferences, including events in Toronto, London, and New York. The company, known for developing therapeutics for immuno-inflammatory diseases, is currently advancing their lead drug candidate, EB05, in a Phase 3 study for ARDS, with plans to initiate a Phase 2 study for pulmonary fibrosis. Additionally, Edesa is exploring treatments for vitiligo and chronic Allergic Contact Dermatitis through its dermatology assets.
For further insights into EDSA stock, check out TipRanks’ Stock Analysis page.